InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-1.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
No signal scores available.
Discover the detailed record of transactions filed by Bernard Gilly, Chief Executive Officer. Officer active across 1 company, notably Gensight Biologics S.A.. In total, 1 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €117k. Activity tracked since 7 April 2022. The latest transaction was disclosed on 7 April 2022 (Acquisition). Regulator: AMF. The full history is free.
Declarations1 total
50,000 shares@ €2.3425100.0% of flowActionEuronext Paris2022DD835024
Ideal exit: 2 Jan 2023 (T+270)
1 of 1 declaration
About Bernard Gilly
Bernard Gilly is the Chief Executive Officer of GenSight Biologics S.A. He is responsible for the strategic and operational direction of the company, which focuses on developing treatments for eye diseases. His experience in the biopharmaceutical sector is an asset for GenSight.
